Analysts See $4.33 EPS for Opiant Pharmaceuticals, Inc. (OPNT)

February 24, 2018 - By Dolores Ford

 Analysts See $4.33 EPS for Opiant Pharmaceuticals, Inc. (OPNT)

Analysts expect Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) to report $4.33 EPS on March, 15.They anticipate $0.58 EPS change or 11.81 % from last quarter’s $4.91 EPS. OPNT’s profit would be $8.95 million giving it 1.30 P/E if the $4.33 EPS is correct. After having $-2.77 EPS previously, Opiant Pharmaceuticals, Inc.’s analysts see -256.32 % EPS growth. The stock decreased 0.84% or $0.19 during the last trading session, reaching $22.44. About 14,831 shares traded. Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) has 0.00% since February 24, 2017 and is . It has underperformed by 16.70% the S&P500.

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company has market cap of $46.40 million. The firm offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It has a 32.71 P/E ratio. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine.

More notable recent Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) news were published by: which released: “Opiant Pharmaceuticals, Inc. Provides an Update on NARCAN® Nasal Spray” on September 15, 2017, also with their article: “Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results” published on December 04, 2017, published: “Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data …” on December 18, 2017. More interesting news about Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) were released by: and their article: “Opiant Pharmaceuticals, Inc., CEO Roger Crystal, MD, to Present to President’s …” published on September 25, 2017 as well as‘s news article titled: “Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from …” with publication date: January 02, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: